Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 21-22/2021

26.03.2021 | perspective

New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy

verfasst von: Prof. Dr. Marco Idzko, Sylvia Hartl, Bernd Lamprecht, Matthias Reisinger, Judith Löffler-Ragg, Markus Rauter, Michael Studnicka, Wolfgang Pohl

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 21-22/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Asthma has been recognized as an inflammatory disease, with chronic airway inflammation underlying bronchial hyperresponsiveness and bronchoconstriction [ 1, 2]. Several studies established the presence of increased numbers of inflammatory cells including eosinophils, dendritic cells, type 2 innate lymphoid cells (ILC2), mast cells and lymphocytes in the lung tissue, bronchoalveolar lavage, and sputum from asthmatic patients [ 17]. Airway inflammation increases at times of exacerbations and is even present in patients with mild asthma despite a relatively low burden of symptoms [ 8]. …

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800. PubMed Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783–800. PubMed
2.
Zurück zum Zitat Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–72. PubMed Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360–72. PubMed
3.
Zurück zum Zitat Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, et al. Eosinophils, T‑lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol. 1991;88(4):661–74. PubMed Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, et al. Eosinophils, T‑lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol. 1991;88(4):661–74. PubMed
4.
Zurück zum Zitat Kirby JG, Hargreave FE, Gleich GJ, O’Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis. 1987;136(2):379–83. PubMed Kirby JG, Hargreave FE, Gleich GJ, O’Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis. 1987;136(2):379–83. PubMed
5.
Zurück zum Zitat Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992;47(1):25–9. PubMedPubMedCentral Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992;47(1):25–9. PubMedPubMedCentral
6.
7.
Zurück zum Zitat Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. PubMed Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56. PubMed
8.
Zurück zum Zitat Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. PubMed Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62(6):591–604. PubMed
11.
Zurück zum Zitat Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev. 2001;4:CD3274. Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev. 2001;4:CD3274.
12.
Zurück zum Zitat Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–6. PubMed Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332–6. PubMed
13.
Zurück zum Zitat Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880–4. PubMedPubMedCentral Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57(10):880–4. PubMedPubMedCentral
14.
Zurück zum Zitat Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108(5):1228–34. PubMed Selroos O, Pietinalho A, Löfroos AB, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995;108(5):1228–34. PubMed
15.
Zurück zum Zitat Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–66. PubMed Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389(10065):157–66. PubMed
17.
Zurück zum Zitat Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119(4):916–23. PubMed Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119(4):916–23. PubMed
18.
Zurück zum Zitat Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83(4):330–3. PubMedPubMedCentral Jónasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child. 2000;83(4):330–3. PubMedPubMedCentral
19.
Zurück zum Zitat Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. PubMedPubMedCentral Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. PubMedPubMedCentral
20.
Zurück zum Zitat Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–6. PubMed Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–6. PubMed
21.
Zurück zum Zitat Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, González-Díaz S, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract. 2015;3(5):734–742.e5. PubMed Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, González-Díaz S, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific Region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract. 2015;3(5):734–742.e5. PubMed
22.
Zurück zum Zitat Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise asthma and link to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. PubMedPubMedCentral Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise asthma and link to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. PubMedPubMedCentral
23.
Zurück zum Zitat Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74. PubMed Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev. 2012;21(123):66–74. PubMed
24.
Zurück zum Zitat Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, et al. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional AND longitudinal assessment on asthma control (liaison) study. Respir Res. 2016;17(1):51. PubMedPubMedCentral Braido F, Brusselle G, Guastalla D, Ingrassia E, Nicolini G, Price D, et al. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional AND longitudinal assessment on asthma control (liaison) study. Respir Res. 2016;17(1):51. PubMedPubMedCentral
25.
Zurück zum Zitat O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3):1701103. PubMed O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J. 2017;50(3):1701103. PubMed
26.
Zurück zum Zitat Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. Eur Respir J. 2018;52(5):1800694. PubMed Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. Eur Respir J. 2018;52(5):1800694. PubMed
27.
Zurück zum Zitat Lenney W, Milner AD, Hiller EJ. Continuous and intermittent salbutamol tablet administration in asthmatic children. Br J Dis Chest. 1979;73(3):277–81. PubMed Lenney W, Milner AD, Hiller EJ. Continuous and intermittent salbutamol tablet administration in asthmatic children. Br J Dis Chest. 1979;73(3):277–81. PubMed
28.
Zurück zum Zitat Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest. 1981;75(2):215–7. PubMed Shepherd GL, Hetzel MR, Clark TJ. Regular versus symptomatic aerosol bronchodilator treatment of asthma. Br J Dis Chest. 1981;75(2):215–7. PubMed
29.
Zurück zum Zitat Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140(10):802–13. PubMed Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med. 2004;140(10):802–13. PubMed
30.
Zurück zum Zitat Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2020;110(6):S322–8. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2020;110(6):S322–8.
31.
Zurück zum Zitat Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β‑agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–7. PubMed Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting β‑agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–7. PubMed
32.
Zurück zum Zitat Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604–10. PubMed Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149(3 Pt 1):604–10. PubMed
33.
Zurück zum Zitat Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79(4):653–9. PubMed Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987;79(4):653–9. PubMed
34.
Zurück zum Zitat Gavreau G, Jordana M, Watson RM, Cockroft DW, O’Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997;156(6):1738–45. Gavreau G, Jordana M, Watson RM, Cockroft DW, O’Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997;156(6):1738–45.
35.
36.
Zurück zum Zitat Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–87. PubMed Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–87. PubMed
37.
Zurück zum Zitat O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. PubMed O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–76. PubMed
38.
Zurück zum Zitat O’Byrne P, Fitzgerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. Eur Respir J. 2018;52(62):OA1680. O’Byrne P, Fitzgerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. Eur Respir J. 2018;52(62):OA1680.
39.
Zurück zum Zitat Buhl R, Kuna P, Peters MJ, Andersson TL, Naya PI, Peterson S, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59. PubMedPubMedCentral Buhl R, Kuna P, Peters MJ, Andersson TL, Naya PI, Peterson S, et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13:59. PubMedPubMedCentral
40.
Zurück zum Zitat Beasley N, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–30. PubMed Beasley N, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–30. PubMed
41.
Zurück zum Zitat Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. PubMed Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. PubMed
42.
Zurück zum Zitat Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, et al. ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J. 2020;55:1901407. PubMed Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, et al. ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma. Eur Respir J. 2020;55:1901407. PubMed
43.
Zurück zum Zitat Licskai C, Yang CL, Lemiere C, Ducharme FM, Lougheed MD, Radhakrishnan D, et al. Are the 2019 global initiative for asthma (GINA) strategy recommendations applicable to the Canadian context? Can J Respir Crit Care Sleep Med. 2020;4(1):3–6. Licskai C, Yang CL, Lemiere C, Ducharme FM, Lougheed MD, Radhakrishnan D, et al. Are the 2019 global initiative for asthma (GINA) strategy recommendations applicable to the Canadian context? Can J Respir Crit Care Sleep Med. 2020;4(1):3–6.
44.
Zurück zum Zitat O’Byrne P, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Alagappan VKT, et al. Efficacy of as-needed budesonide/formoterol for reducing severe exacerbations in adolescents with mild asthma: pooled subgroup analysis of the SYGMA 1 and 2 trials. Am J Respir Crit Care Med. 2020;201:A7191. O’Byrne P, Bateman ED, FitzGerald JM, Barnes PJ, Zhong N, Alagappan VKT, et al. Efficacy of as-needed budesonide/formoterol for reducing severe exacerbations in adolescents with mild asthma: pooled subgroup analysis of the SYGMA 1 and 2 trials. Am J Respir Crit Care Med. 2020;201:A7191.
Metadaten
Titel
New insights from GINA 2019/2020—Focus on early anti-inflammatory therapy
verfasst von
Prof. Dr. Marco Idzko
Sylvia Hartl
Bernd Lamprecht
Matthias Reisinger
Judith Löffler-Ragg
Markus Rauter
Michael Studnicka
Wolfgang Pohl
Publikationsdatum
26.03.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 21-22/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01830-1